Show All
What is Allogene’s official name?
Our official name is Allogene Therapeutics, Inc.
Where is Allogene headquartered?
Allogene is headquartered in South San Francisco, CA.

Our mailing address is:
210 East Grand Avenue
South San Francisco, CA 94080
When was Allogene founded?
Allogene was incorporated in November 2017.
When was Allogene’s IPO?
Allogene’s initial public offering was on October 10, 2018.
On which exchange does Allogene’s stock trade and what is its stock symbol?
Allogene’s common stock is traded on the Nasdaq Global Select Market under the symbol ALLO.
How can I buy or sell shares of Allogene?
Allogene does not offer a direct purchase plan for investors. You may purchase Allogene’s common stock through a licensed securities broker.
Who is Allogene’s Transfer Agent?
Our transfer agent is:

EQ Shareowner Services
Attn: Customer Service
PO Box 64874
St. Paul, MN 55164-0874

Who do I contact regarding lost stock certificates, address changes, and changes of ownership or name in which shares are held?
If your shares are held in street name (i.e., through your brokerage account), you must contact your broker.

If your shares held directly by you in your name, please contact our transfer agent:

EQ Shareowner Services
Attn: Customer Service
PO Box 64874
St. Paul, MN 55164-0874

Will Allogene issues dividends on its common stock?
Allogene does not anticipate paying cash dividends on its common stock for the foreseeable future.
Who are Allogene’s independent auditors?
Allogene’s independent auditors are Ernst & Young LLP.
Who is Allogene’s outside legal counsel?
Allogene’s outside legal counsel is Cooley LLP.
When is Allogene’s fiscal year end?
Our fiscal year end is December 31st.
How can I get a copy of Allogene’s Form S-1 or any other public filings?
Our SEC filings, when available, are listed on the SEC's web site, You may also find our filings in our Investor Relations Center on this website.
If I have questions regarding Allogene, how do I contact Allogene’s Investor Relations?
Please email for assistance with Investor Relations questions.